

IMAGION BIOSYSTEMS LIMITED

ASX: IBX

25 August 2023

Convertible Note Investment

MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, has received \$1,000,000 from Mercer Street Global Opportunity Fund, LLC, a US-based investment fund managed by Mercer Street Capital Partners, LLC (together, “Mercer”) pursuant to the convertible note agreement between the Company and Mercer announced on the ASX on 7 March 2023.

The Company will now proceed to issue 1,100,000 convertible notes with a face value of \$1 each, and 46,583,851 options in accordance with the terms of the convertible note agreement. Full details of these securities are set out in the Company's other ASX announcements dated 7 March 2023 and 25 August 2023. The issue of these securities was approved by shareholders on 25 May 2023.

The Company will use this funding to advance clinical development the Company's lead imaging agent as well as for other general working capital expenses.

— ENDS —

About Imagion Biosystems

Established in 2017 and headquartered in the San Diego, California, US, Imagion Biosystems is an ASX-listed company dedicated to developing innovative medical imaging technologies for various cancer types. Imagion Biosystems is advancing clinical development of its MagSense® platform technology to revolutionize cancer diagnosis, introducing molecular imaging to MRI. The Company's lead program has demonstrated its innovative technology embodied in MagSense® HER2 Imaging Agent (MSH2IA) is safe and well-tolerated in patients with diagnosed HER2+ breast cancer. Imagion Biosystems' MagSense® pipeline includes prostate cancer, ovarian cancer, and brain cancer programs advancing towards clinical development.

For more information, visit <https://imagonbiosystems.com/investor-hub/>



Imagion Biosystems Interactive Investor Hub

Engage with us directly by asking questions, watching video summaries, and seeing what other shareholders have to say about this and past announcements at our Investor Hub:

<https://investorhub.imagionbiosystems.com/>

Authorisation & Additional information

This announcement was authorised by the Board of Imagion Biosystems Limited.

Australian Media & Investor Relations:

Geoff Hollis, CFO and Company Secretary
geoff.hollis@imagionbio.com
+61 438 168 008

U.S. Media Contact

Casie Ost
casie.ost@imagionbio.com
+1-619-693-4428

